公开(公告)号：US20190249138A1

公开(公告)日：2019-08-15

申请号：US16120040

申请日：2018-08-31

Applicant: Janssen Biotech, Inc. ,  Nunc A/S

Inventor： Benjamin Fryer ,  Shelley Nelson ,  Villy Nielsen ,  Tina Kristensen Marwood ,  Thomas Brevig

IPC: C12N5/0735

CPC classification number: C12N5/0606 ,  C12N2501/70 ,  C12N2509/00 ,  C12N2533/00

Abstract: The present invention relates to the field of mammalian cell culture, and provides methods and compositions for cell attachment to, cultivation on and detachment from a solid substrate surface containing from at least about 0.5% N, a sum of O and N of greater than or equal to 17.2% and a contact angle of at least about 13.9 degrees, lacking a feeder cell layer and lacking an adlayer. In one embodiment of the present invention, the cells are treated with a compound capable of inhibiting Rho kinase activity. In another embodiment, the cells are treated with a compound capable of inhibiting Rho activity.

公开(公告)号：US20190175651A1

公开(公告)日：2019-06-13

申请号：US16215716

申请日：2018-12-11

Applicant: Janssen Biotech, Inc.

Inventor： John Lee ,  Jill Mooney ,  Michael Naso

IPC: A61K35/17 ,  C07K14/78 ,  C07K14/47 ,  C07K14/705 ,  C07K14/715 ,  A61P35/00 ,  C12N15/85 ,  C12N15/90

Abstract: The present invention pertains to engineered immortalized T-cell lines, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immortalized T-cell lines of the invention are characterized in that the expression of endogenous T-cell receptors (TCRs) and beta 2-microglobulin (B2M) is inhibited, e.g., by using an endonuclease able to selectively inactivate the TCR and B2M genes in order to render the immortalized T-cells non-alloreactive. In addition, expression of immunosuppressive polypeptide can be performed on those engineered immortalized T-cells in order to prolong the survival of these T-cells in host organisms. Such engineered immortalized T-cells are particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the host's immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immortalized T-cells for treating cancer, infections and auto-immune diseases.

公开(公告)号：US20190135912A1

公开(公告)日：2019-05-09

申请号：US16184270

申请日：2018-11-08

Applicant: Janssen Biotech, Inc.

Inventor： Ellen Chi ,  Judith Connor ,  Chichi Huang ,  Jarrat Jordan ,  Xiefan Lin-Schmidt ,  Jinquan Luo ,  Lu Lu ,  Christian Martinez ,  Galina Obmolova ,  Ronald Swanson

IPC: C07K16/24

Abstract: Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are usefule in the treatment of diseases associated with increased production of IFNα and IFNω.

公开(公告)号：US20190135910A1

公开(公告)日：2019-05-09

申请号：US16181733

申请日：2018-11-06

Applicant: Janssen Biotech, Inc.

Inventor： Elizabeth Hsia ,  Lillian Xu

IPC: C07K16/24 ,  A61P19/02 ,  A61K47/68 ,  G16H50/30 ,  A61K9/00

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, PASI70/90/100, MDA, HAQ-DI, SF-36 PCS, MCS, LEI/dactylitis, PASDAS, GRACE, mCPDAI, DAPSA or RAPID3 improvement as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US20190106489A1

公开(公告)日：2019-04-11

申请号：US16222285

申请日：2018-12-17

Applicant: Janssen Biotech, Inc.

Inventor： Ellen Chi ,  Judith Connor ,  Chichi Huang ,  Jarrat Jordan ,  Xiefan Lin-Schmidt ,  Jinquan Luo ,  Lu Lu ,  Christian Martinez ,  Galina Obmolova ,  Ronald Swanson

IPC: C07K16/24 ,  A61K38/13 ,  A61K45/06

CPC classification number: C07K16/249 ,  A61K38/13 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

公开(公告)号：US10228381B2

公开(公告)日：2019-03-12

申请号：US15648085

申请日：2017-07-12

Applicant: Emulate Inc. ,  JANSSEN BIOTECH, Inc

Inventor： Daniel Levner ,  Christopher David Hinojosa ,  Norman Wen ,  Jacob Fraser ,  Justin Nguyen ,  Riccardo Barrile ,  Geraldine Hamilton ,  Catherine Karalis ,  Hyoungshin Park ,  Antonio Varone ,  Andries Van der Meer ,  Monicah Otieno ,  David Conegliano

IPC: B01L3/00 ,  G01N33/50 ,  G01N33/569 ,  C12M1/00 ,  C12M3/00 ,  G01N33/86 ,  C12M3/06 ,  C12M1/42 ,  C12M1/34 ,  G01N33/543 ,  G01N35/08

Abstract: Compositions, devices and methods are described for preventing, reducing, controlling or delaying adhesion, adsorption, surface-mediated clot formation, or coagulation in a microfluidic device or chip. In one embodiment, blood (or other fluid with blood components) that contains anticoagulant is introduced into a microfluidic device comprising one or more additive channels containing one or more reagents that will re-activate the native coagulation cascade in the blood that makes contact with it “on-chip” before moving into the experimental region of the chip.

公开(公告)号：US20190010466A1

公开(公告)日：2019-01-10

申请号：US16119995

申请日：2018-08-31

Applicant: Janssen Biotech, Inc.

Inventor： Alireza Rezania

IPC: C12N5/071

Abstract: The present invention provides methods to promote differentiation of pancreatic endoderm cells to pancreatic endocrine rich clusters and to enhance insulin expression in hormone-expressing cells.

公开(公告)号：US20180344777A1

公开(公告)日：2018-12-06

申请号：US15988821

申请日：2018-05-24

Applicant: Janssen Biotech, Inc.

Inventor： Ian R. Harris ,  Nadine S. Dejneka

IPC: A61K35/51 ,  A61P27/00 ,  A61P25/00 ,  A61K35/30

Abstract: Methods and compositions for treating ophthalmic disease, in particular retinal degeneration, including modulating Müller glia, restoring retinal synaptic connectivity and forming α2δ1-containing synapses, using postpartum-derived cells are disclosed.

公开(公告)号：US10087243B2

公开(公告)日：2018-10-02

申请号：US15584235

申请日：2017-05-02

Applicant: New York University ,  Janssen Biotech, Inc.

Inventor： Victor J. Torres ,  Randall J. Brezski ,  Anthony Lynch ,  William Strohl ,  Brian Whitaker ,  Mark Chiu ,  Peter T. Buckley ,  Keri Dorn ,  Michelle Kinder

IPC: C07K19/00 ,  C07K16/12 ,  C07K14/78

Abstract: The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.

公开(公告)号：US10066210B2

公开(公告)日：2018-09-04

申请号：US13911829

申请日：2013-06-06

Applicant: Janssen Biotech, Inc.

Inventor： Alireza Rezania

IPC: C12N5/00 ,  C12N5/071

CPC classification number: C12N5/0676 ,  C12N2501/50 ,  C12N2501/998 ,  C12N2506/02

Abstract: The present invention provides methods to promote differentiation of pancreatic endoderm cells to pancreatic endocrine rich clusters and to enhance insulin expression in hormone-expressing cells.